Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
Top Page
Neumora Therapeutics, Inc.
(NASDAQ:NMRA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▼(-14.16% Downside)
Action:ReiteratedDate:01/13/26
The score is held back primarily by weak financial performance (no revenue, large ongoing losses, and significant cash burn), partially offset by constructive technical positioning (price above key moving averages with moderately strong RSI) and positive, catalyst-rich corporate pipeline updates. Valuation metrics provide limited support due to the negative P/E and no dividend yield provided.
Positive Factors
Clinical efficacy signal (NMRA-511)
A clinically meaningful Phase 1b signal with favorable safety for NMRA-511 is a durable pipeline milestone that justifies advancement into higher-dose extensions and Phase 2/3 planning. This reduces binary program risk and strengthens Neumora’s strategic position in an unmet Alzheimer’s agitation market.
Negative Factors
Pre-revenue with large losses
Sustained, large operating and net losses reflect an extended development-only business model with no recurring revenue to absorb costs. Over the medium term this necessitates external funding, increases dilution risk, and leaves no internal cash buffer to self-fund multiple late-stage programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy signal (NMRA-511)
A clinically meaningful Phase 1b signal with favorable safety for NMRA-511 is a durable pipeline milestone that justifies advancement into higher-dose extensions and Phase 2/3 planning. This reduces binary program risk and strengthens Neumora’s strategic position in an unmet Alzheimer’s agitation market.
Read all positive factors
Neumora Therapeutics, Inc. (NMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$389.32M
Dividend YieldN/A
Average Volume (3M)490.26K
Price to Earnings (P/E)―
Beta (1Y)2.61
Revenue GrowthN/A
EPS Growth20.71%
CountryUS
Employees110
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding167,089,110
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio-2.58
Price to Book (P/B)5.89
Price to Sales (P/S)0.00
P/FCF Ratio-9.23
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-52.15
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$10.80Price Target Upside363.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$625.00K
Neumora Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a nov...
How the Company Makes Money
Neumora Therapeutics, Inc. generates revenue through the development and commercialization of its precision medicines. The company focuses on advancing its pipeline of investigational therapies through various stages of clinical trials, aiming for...
Neumora Therapeutics, Inc. Earnings Call Summary
Earnings Call Date:Aug 06, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call reflected a company with a strong pipeline and financial position, with significant upcoming clinical milestones that could create substantial value. However, the continued net loss and competitive challenges in the obesity market were noted as areas of concern.Positive Updates
Pipeline Prioritization
Neumora has prioritized obesity as the lead indication for NMRA-215, an NLRP3 inhibitor with high CNS penetration, citing the potential for substantial improvements over current therapies.
Negative Updates
Continued Net Loss
The total net loss for the second quarter was $52.7 million, a slight decrease from $58.7 million in the same period in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Pipeline Prioritization
Neumora has prioritized obesity as the lead indication for NMRA-215, an NLRP3 inhibitor with high CNS penetration, citing the potential for substantial improvements over current therapies.
Read all positive updates
Company Guidance
During the recent Neumora Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided extensive guidance on its future strategic initiatives and clinical developments. Neumora highlighted its prioritization of obesity as the lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with plans to initiate clinical studies in the first quarter of 2026. The company expects up to six clinical data readouts over the next 18 months, including Phase Ib data for NMRA-511 in Alzheimer's disease agitation by the end of the year, and top-line data from the Phase III KOASTAL program with navacaprant in major depressive disorder anticipated in early 2026. Additionally, Neumora disclosed a robust financial standing with $217.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, supporting operations into 2027. The company aims to leverage its expertise in neuroscience to address prevalent brain diseases and improve patient outcomes, while maintaining a strong development pipeline.Neumora Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.00M | 0.00 | -668.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -243.55M | -262.83M | -187.53M | -135.28M | -236.78M | -95.41M |
| Net Income | -236.30M | -243.79M | -235.93M | -130.90M | -237.31M | -99.27M |
Balance Sheet | ||||||
| Total Assets | 177.83M | 316.97M | 496.19M | 426.23M | 429.30M | 197.95M |
| Cash, Cash Equivalents and Short-Term Investments | 171.53M | 307.58M | 453.98M | 371.88M | 409.25M | 191.98M |
| Total Debt | 523.00K | 1.85M | 5.23M | 8.44M | 2.05M | 2.04M |
| Total Liabilities | 45.67M | 29.91M | 27.12M | 873.08M | 754.52M | 292.33M |
| Stockholders Equity | 132.16M | 287.06M | 469.08M | -446.85M | -325.22M | -94.38M |
Cash Flow | ||||||
| Free Cash Flow | -208.84M | -182.94M | -163.40M | -115.41M | -76.24M | -28.06M |
| Operating Cash Flow | -208.82M | -182.94M | -163.28M | -114.90M | -75.42M | -26.76M |
| Investing Cash Flow | 27.07M | -70.56M | 64.39M | -168.01M | -817.00K | -11.24M |
| Financing Cash Flow | 33.89M | 21.60M | 231.94M | 115.74M | 293.51M | 230.10M |
Neumora Therapeutics, Inc. Technical Analysis
Negative
2.33
Price Trends
2.71
Negative
2.46
Negative
2.04
Positive
Market Momentum
-0.14
Positive
31.58
Neutral
9.93
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMRA, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 2.85, below the 50-day MA of 2.71, and above the 200-day MA of 2.04, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 31.58 is Neutral, neither overbought nor oversold. The STOCH value of 9.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMRA.
Neumora Therapeutics, Inc. Risk Analysis
Neumora Therapeutics, Inc. disclosed 79 risk factors in its most recent earnings report. Neumora Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neumora Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $389.32M | -1.30 | -113.81% | ― | ― | 20.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $550.94M | -1.58 | -57.07% | ― | -100.00% | 37.10% | |
47 Neutral | $244.74M | 3.92 | 53.18% | ― | ― | ― | |
47 Neutral | $267.15M | -3.73 | -101.60% | ― | -89.01% | -86.17% | |
44 Neutral | $77.45M | -4.47 | -48.06% | ― | ― | 31.30% |
* Healthcare Sector Average
NMRA
Neumora Therapeutics, Inc.
2.33
1.33
133.00%
ABEO
Abeona Therapeutics
4.29
-0.47
-9.87%
ACIU
AC Immune SA
2.70
0.83
44.39%
ALLO
Allogene Therapeutics
2.26
0.80
54.79%
AARD
Aardvark Therapeutics, Inc.
3.55
-3.96
-52.73%
Neumora Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Neumora outlines 2026 neuroscience pipeline and obesity plans
Positive
Jan 12, 2026
On January 12, 2026, Neumora Therapeutics made a new corporate presentation available for use at the 44th Annual J.P. Morgan Healthcare Conference, outlining its mission to redefine neuroscience drug development and its plan to advance three core ...
Business Operations and StrategyProduct-Related Announcements
Neumora reports promising Phase 1b results in Alzheimer’s agitation
Positive
Jan 5, 2026
On January 5, 2026, Neumora Therapeutics reported positive results from a Phase 1b signal-seeking study of NMRA-511, an oral, highly potent and selective vasopressin 1a receptor antagonist, in people with agitation associated with Alzheimer’...
Private Placements and FinancingRegulatory Filings and Compliance
Neumora Issues Shares Following Loan Conversion Notice
Neutral
Nov 21, 2025
On November 17, 2025, Neumora Therapeutics received a conversion notice from K2 HealthVentures, electing to convert $2.5 million of a term loan into common stock at a price of $0.8774 per share. Subsequently, on November 20, 2025, Neumora issued 2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.